Acetamide → HCID 59631275、化合物
反応式
Cl[C:2]1[CH:3]=[C:4]([CH:14]([C:16]2[C:25]3[C:20](=[CH:21][C:22]([F:26])=[CH:23][CH:24]=3)[N:19]=[C:18]([C:27]3[CH:32]=[CH:31][CH:30]=[CH:29][N:28]=3)[C:17]=2[CH3:33])[OH:15])[CH:5]=[C:6]([N:8]2[CH2:13][CH2:12][O:11][CH2:10][CH2:9]2)[CH:7]=1.P([O-])([O-])([O-])=O.[K+].[K+].[K+].[C:42]([NH2:45])(=[O:44])[CH3:43]>C([O-])(=O)C.[Pd+2].C([O-])(=O)C.C(O)(C)(C)C>[F:26][C:22]1[CH:21]=[C:20]2[C:25]([C:16]([CH:14]([OH:15])[C:4]3[CH:3]=[C:2]([NH:45][C:42](=[O:44])[CH3:43])[CH:7]=[C:6]([N:8]4[CH2:13][CH2:12][O:11][CH2:10][CH2:9]4)[CH:5]=3)=[C:17]([CH3:33])[C:18]([C:27]3[CH:32]=[CH:31][CH:30]=[CH:29][N:28]=3)=[N:19]2)=[CH:24][CH:23]=1参加物
実験手順
Prepared according to Procedure W by stirring palladium (II) acetate (1.5 mg, 6.70 μmol), tetramethyl tert-butyl XPhos (9.7 mg, 0.020 mmol), (3-chloro-5-morpholinophenyl)(7-fluoro-3-methyl-2-(pyridin-2-yl)quinolin-4-yl)methanol (0.031 g, 0.067 mmol), tripotassium phosphate (0.020 g, 0.094 mmol), acetamide (4.8 mg, 0.080 mmol), and tert-butanol (0.9 mL) at 110° C. for 1 hour. Purification by reverse-phase HPLC afforded N-(3-((7-fluoro-3-methyl-2-(pyridin-2-yl)quinolin-4-yl)(hydroxy)methyl)-5-morpholinophenyl)acetamide as a white amorphous solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 9.67 (1H, s), 8.70 (1H, d), 8.39 (1H, m), 8.02 (1H, t), 7.80 (1H, d), 7.70 (1H, d), 7.52 (1H, m), 7.39 (1H, t), 7.32 (1H, s), 6.87 (1H, s), 6.60 (1H, s), 6.52 (1H, d), 6.48 (1H, s), 3.72 (4H, t, J=4.7 Hz), 3.03 (4H, d, J=3.3 Hz), 2.47 (3H, s), 1.91 (3H, s). Mass Spectrum (ESI) m/e=467.2 (M+1).
後処理
- customPrepared
- customPurification by reverse-phase HPLC
出典と根拠
- ORDレコード
- ord-5478625ffa8c427db77b3ed1eb073a87
- 出典データセット
- uspto-grants-2015_01
- 特許番号
- US08940724B2
反応ノート
読み込み中…